Exploring systemic options for advanced hepatocellular carcinoma

ISBN-13: 9783659430138 / Angielski / Miękka / 2013 / 168 str.

Abdel-Rahman Omar

Opis

The only approved systemic therapy for patients with advanced hepatocellular carcinoma (HCC) till now is sorafenib. A preliminary study suggested that capecitabine, an oral fluoropyrimidine, may be effective in advanced HCC. We have tested this hypothesis in this phase 2 study. In this single-center, phase 2, open-label trial, we randomly assigned 52 patients with advanced HCC who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or capecitabine (1,000 mg/m2 twice daily) (day 1-day 14). Primary outcome was progression-free survival. Secondary outcomes included the overall survival and safety.

O autorze

Omar Abdel-Rahman,M.B,B.Ch.,M.Sc.,Assistant lecturer of clinical oncology,faculty of medicine,Ain shams university,Cairo